CRSP241108P30000
- 0.00
- 0.000.00%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics | 10-Q: Quarterly report
Crispr Therapeutics Reports Q3 EPS ($1.01), Consensus ($1.42)
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q3 Revenue $602,000
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Crispr Therapeutics 3Q Loss/Shr $1.01 >CRSP
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Crispr Therapeutics AG (CRSP) Gets a Buy From Mizuho Securities
Crispr Therapeutics Options Imply 8.9% Move in Share Price Post-earnings
Editas Downgraded to Market Perform by Raymond James
Earnings Week Ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and More
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations
We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth
Cathie Wood's ARK Investment Bought 34K Shares of Crispr Therapeutics Today